Category Archives: Biology

Biologist Beth Shapiro on the ‘de-extinction’ of woolly mammoths – STAT

Humans have long tinkered with the evolutionary trajectories of other species. Thousands of years ago we tamed wolves into dogs and transformed a wild grass into the agricultural wonder wheat. Within the past few centuries, we exterminated the Tasmanian tiger and doomed the dodo bird to oblivion. Now, we stand on the brink of an ambitious new era in how humans may transfigure life around us: by pursuing the science of de-extinction, or the resurrection of species once lost to this world.

Beth Shapiro is an evolutionary biologist, an ancient DNA adventurer who has collected fossilized bison bones from Arctic permafrost, and a titan in the de-extinction movement. She co-led the Paleogenomics Lab at the University of California, Santa Cruz, was a Howard Hughes Medical Institute investigator and a MacArthur Fellow, and is the author of the books How to Clone a Mammoth: The Science of De-Extinction and Life as We Made It: How 50,000 Years of Human Innovation Refinedand RedefinedNature. In 2022 she announced that her team sequenced the genome of the dodo bird.

Recently, Shapiro was named chief scientific officer of Colossal Biosciences, a biotech company with its sights set on bringing back such fallen fauna as the woolly mammoth, dodo bird and Tasmanian tiger, or thylacine. Shapiro spoke with STAT about CRISPR, conservation, and her recent move from academia to biotech. She also discussed how the scientific journey to reviving extinct species may provide insight into better protecting and preserving ecosystems in the present day. This interview has been edited for length and clarity.

How did your interest in de-extinction start?

I have worked in ancient DNA for my whole graduate career since 1999, when I joined Alan Coopers group in Oxford. I was fascinated by this combination of paleontology, evolutionary biology, and molecular biology. At that time, it was just beginning. It was crazy to think that we could actually recover DNA sequences from things that had been dead for tens of thousands of years, and then use that to try to better understand how species, populations, communities, and entire ecosystems shift and change over evolutionarily significant time scales.

Whenever we would publish one of these papers, often we got a lot of media attention, and it was very exciting to think about mammoth DNA, ancient bison, or extinct horses. But really, the question that they were most interested in asking us was, What does this mean about bringing extinct species back to life? At first it was disappointing. I really wanted to talk about the cool stuff that were learning, and all they wanted to talk about is Jurassic Park or Pleistocene Park. But then, you start to understand its that type of question that engages people with the science.

Gradually over my career, Ive just gotten more and more engaged with what [de-extinction] would actually look like. Ive really begun to appreciate how the technologies one would need in order to bring back something similar to a mammoth are exactly the types of technologies we need to be able to protect and preserve species that are still alive today but in danger of becoming extinct like the mammoth did. That is where my pure excitement about this technology lives, in this whole wealth of new biotechnologies that we have at our fingertips that we should be able to use for endangered species preservation.

Are you sick and tired of the Jurassic Park comparisons at this point? Especially now that youre working for Colossal full-time as their chief scientific officer?

Not at all. In the very beginning when it was the only question that I got, I got tired of hearing this question. But now I realize that this is why kids are paying attention. This is why my mother is paying attention. Mostly science is in the noise for people who arent actively working in science. But the extinction crisis shouldnt be in the noise. And if it takes people thinking to themselves, Oh, my goodness, theres a real company out there doing Jurassic Park which were not I better read up on this and find something out, then weve won. There are a bunch of people who wouldnt have cared at all about extinction who now are thinking about it.

What does the jump from academia to biotech look like for you?

Its a big jump right now. I am a little bit terrified, but really excited. I think academics are not very good at risk-taking. This is certainly a risky move, but this is a combination of all of the hardest problems in biology.

I think that is where I started in ancient DNA: Its really hard to get DNA out of old things, and that was exciting. Its not actually so hard to do that anymore now. Then it was really hard to figure out exactly how we were going to use that to learn about population history. And now we kind of got that. But now the big hard thing is how do we translate these genome sequences of extinct species into better understanding why these species looked and acted the way that they did, so that we can use that information to learn about preservation of species today. That is now, I think, one of the hardest problems in biology. It is definitely not something that I can tackle on my own in my academic lab.

So what is de-extinction?

When most people hear the word de-extinction, what comes to mind immediately is cloning something. Im going to clone a mammoth. But in order to clone a mammoth, you need a living cell. You need an intact nuclear genome of a mammoth, and that just doesnt exist anymore. Once an organism dies, the DNA in all of its cells starts to get broken down into smaller and smaller pieces, until eventually theres nothing left. Our job as ancient DNA scientists is to try to figure out how to pull those tiny, broken pieces of DNA out of these cells. But that is not the same thing as having an intact cell, an intact nucleus.

What we actually mean when we talk about de-extinction now is using the tools of genome engineering to resurrect the core traits of these species that used to be there. Were not creating a mammoth. Were taking an Asian elephant and helping it to become something that is more similar to a mammoth by resurrecting the capacity to live in colder climates. One thing thats cool about this is it means we have to understand what it is that made a mammoth able to live in colder climates. We start to learn about how these sorts of traits evolve, and what is it in the genome that drives cold tolerance? A hard question, but we need to know that if were going to drive those traits into an Asian elephant. When I think of de-extinction, I think of resurrecting these core phenotypes, these core traits.

What role does CRISPR play in de-extinction and bringing back the mammoth?

What we have now is the genome sequences of several dozen, maybe more, mammoth genomes lined up against each other on a computer. And we have a bunch of sequences of Asian elephants and African elephants also on a computer. We line them up next to each other, and we can look at these sequences and ask, Where in the genome are all the mammoths like each other but different from the elephants? This gives us an idea of potentially where some mammoth-specific mutations might be in the genome.

Where does CRISPR come in? We dont have a living cell that is a mammoth. We have our elephant cell, and in that elephant cell we have the elephant genome. And we know very specific places in that genome where we want to tweak the DNA sequence to make that sequence more mammoth-like. We know which parts we want to change because weve compared all the mammoth and elephant genomes and identified the mutations we want to make. That is where we need to use the tools of genome engineering like CRISPR. We will use CRISPR to genetically modify that elephant genome sequence so it looks increasingly more mammoth-like.

Where is Colossal right now on its journey to de-extincting a mammoth?

Eriona [Hysolli]s team the mammoth team they understand that we have all of the core technologies that we would need to create a mammoth, but what we need to do is, tune them, tweak them, and make them all apply to elephant cells. They are able to genetically modify the genome sequence of elephants in elephant cells growing in a dish in a lab. They have the capacity to be able to make those edits. Theyre working on new tools like multiplex genome editing, because we know that there are a lot of edits that we have to make. At the same time, she has an embryology team thats really focused on taking those genetically modified cells and pushing them toward that next step.

Speaking about embryology, Colossal made an announcement last month about taking skin cells from elephants and turning them into stem cells. Could you tell me more about that?

One of the tools that would make it much simpler to work with elephants is if we could take elephant cells and make them into stem cells. If you had elephant stem cells, you can actually use that to make elephant egg cells and then we dont have to actually ask for elephant egg cells from elephants. Instead, we can just make them in the lab. That is a huge advance both technologically and ethically. The announcement that the team had succeeded in making elephant stem cells for the first time really speaks to some of the innovations that are going on at Colossal.

Lets get into the ethics of this work. Shouldnt something thats extinct stay extinct?

Extinction and speciation are important processes in evolution. But what we know right now is that the rate of extinction today is somewhere on the order of 1,000 to 10,000 times faster than the average across the fossil record. Much of this is because of things that people are doing. In many cases, the pace of change is too fast for evolution by natural selection to keep up.

A lot of people see this as two choices: We either choose to intervene or we choose not to intervene. But by making that choice, the choice not to intervene, we are still choosing to do something. In this case, we are choosing to watch all of these species become extinct. And that is also a choice.

I get what success would look like: bringing back a woolly mammoth. But what would failure look like in this case? At what point would you say we cant de-extinct a mammoth?

Im really not worried about failure in this case. To me, I think there are so many successes that come on the path toward de-extinction that will have immediate application for conservation of living species. Elephant iPSCs [induced pluripotent stem cells] are not only good for mammoth de-extinction, theyre also good for work that people want to do with elephants. We want to be able to help elephants thrive in habitats of today and tomorrow, including habitats that include diseases that have been introduced by people. This provides the capacity to do that.

The multiplex genome editing technologies that are being developed, the artificial womb technologies that are being developed, these all have applications outside of mammoth de-extinction, including to help people. There are so many successes along the path that I would find it hard to see a place where there is failure.

What is it that Colossal is doing that can actually impact me as a human?

Along the path to mammoth or dodo or thylacine, Colossal will be developing technologies that have immediate application outside of those specific applications. There are millions of evolutionary differences between an Asian elephant and a mammoth, and its unlikely that making one or two small changes is going to create the mammoth phenotype in an Asian elephants genetic background. We need tools for multiplex genome editing, for introducing large fragments of DNA, all of which will have application to using CRISPR gene editing technologies in humans and other species.

How might this work provide us with better insight into human health?

One of the hardest problems in biology right now is understanding how the long stretches of As and Cs and Gs and Ts that make up the genome translate into the way a person or an organism looks and acts, and that includes disease manifestations. We have hundreds of thousands of human genomes, and we still cant pinpoint with precision what gene means what phenotype. One of the ways that were going to get there is through comparative genomics, and that includes species outside of our own. So if we are building these resources where we have genomes from across the tree of life, and more complete understanding of how DNA translates into the way something looks or acts, we will be able to apply this to making more informed decisions or hypotheses that will drive future experiments to understand the link between genotype and disease.

Beyond the charismatic creatures that we often think about when it comes to de-extinction, like the mammoth, the dodo, the thylacine, what animal would you like to de-extinct?

I have my conservation biologist hat on. What other groups of organisms are most in danger of becoming extinct that pushing this technology toward might help them to survive? Insects are highly endangered. Should we be thinking about developing tools and technologies to do CRISPR gene editing in insects?

I think we choose the charismatic animals because its exciting. How do we excite other people about an insect? Well, theres the Xerces blue butterfly [which human activity drove to extinction in the 1940s in the San Francisco Bay] thats beautiful and charismatic. Should we think about that as a mechanism of developing tools that might be applicable across the order of insects that are out there?

Why should a biotech company be thinking about conservation? Why is de-extinction the best allocation of those resources as opposed to more traditional approaches to conservation?

I think conservation is everybodys responsibility, and I know that there are many of the investors in Colossal who have invested in more traditional aspects of conservation as well. My answer is often, yes, we should invest this much money in traditional approaches to conservation, but we also should be investing this money into developing new tools for conservation. Because while traditional approaches to conservation are great and have had some successes, we still have this exceptionally high rate of extinction. We should be thinking about how to grow our conservation toolkit as we move forward.

Whats the biggest barrier to doing de-extinction work right now? Is it ethics, public sentiment, research funding, or just people thinking that genetically modified animals are scary?

All of these are barriers to some extent, but theyre all also surmountable. I think as scientists, we need to do a better job making sure that were reaching out and communicating with people about what it is that we are doing and what it is that were not doing. I think theres a lot of noise out there that is imagining that were doing something crazier than we actually are doing. I think there are technological barriers that are different for every one of the species that are there, ethical, ecological, theyre all the same.

You said your colleagues Eriona Hysolli and George Church think that maybe in 2028 we could see the first live mammoths. What happens next?

That is way earlier than theyll ever be out in the wild wandering around, which means that we have a lot of time to engage with people.

The goal that Eriona and George and Colossal have set up is to reintroduce these animals into the wild. I know that Ben [Lamm, co-founder and CEO of Colossal] has been having conversations with local governments and Indigenous groups in Alaska and elsewhere about where would these animals go or what we need to do in preparation for this. But this is a long way in the future, and, I think exactly what happens to them really needs to be the decision made by the Indigenous groups and the local people that are on the ground.

You have the mammoth team. You have the thylacine team. You have the dodo bird team. Will there ever be a Neanderthal de-extinction team?

Neanderthals were people, and if youre going to work on people, you need to get informed consent. I dont know how you would get informed consent from a Neanderthal that you wanted to bring back to life. But I will say, from a scientific perspective and not from a classical perspective, we have somewhere between 1% and 4% Neanderthal in our DNA. Less well known is that its not the same 1% to 4%. If you go around the planet and you collect all the bits of Neanderthal DNA that survive in people who are alive today, we can put together around 93% of the Neanderthal genome. So Ill just end this by asking you if 93% of their genome exists today, are they really extinct?

See the original post here:

Biologist Beth Shapiro on the 'de-extinction' of woolly mammoths - STAT

MCC students inducted into new honor society geared toward biology – Mohave Valley News

State Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington Washington D.C. West Virginia Wisconsin Wyoming Puerto Rico US Virgin Islands Armed Forces Americas Armed Forces Pacific Armed Forces Europe Northern Mariana Islands Marshall Islands American Samoa Federated States of Micronesia Guam Palau Alberta, Canada British Columbia, Canada Manitoba, Canada New Brunswick, Canada Newfoundland, Canada Nova Scotia, Canada Northwest Territories, Canada Nunavut, Canada Ontario, Canada Prince Edward Island, Canada Quebec, Canada Saskatchewan, Canada Yukon Territory, Canada

Zip Code

Country United States of America US Virgin Islands United States Minor Outlying Islands Canada Mexico, United Mexican States Bahamas, Commonwealth of the Cuba, Republic of Dominican Republic Haiti, Republic of Jamaica Afghanistan Albania, People's Socialist Republic of Algeria, People's Democratic Republic of American Samoa Andorra, Principality of Angola, Republic of Anguilla Antarctica (the territory South of 60 deg S) Antigua and Barbuda Argentina, Argentine Republic Armenia Aruba Australia, Commonwealth of Austria, Republic of Azerbaijan, Republic of Bahrain, Kingdom of Bangladesh, People's Republic of Barbados Belarus Belgium, Kingdom of Belize Benin, People's Republic of Bermuda Bhutan, Kingdom of Bolivia, Republic of Bosnia and Herzegovina Botswana, Republic of Bouvet Island (Bouvetoya) Brazil, Federative Republic of British Indian Ocean Territory (Chagos Archipelago) British Virgin Islands Brunei Darussalam Bulgaria, People's Republic of Burkina Faso Burundi, Republic of Cambodia, Kingdom of Cameroon, United Republic of Cape Verde, Republic of Cayman Islands Central African Republic Chad, Republic of Chile, Republic of China, People's Republic of Christmas Island Cocos (Keeling) Islands Colombia, Republic of Comoros, Union of the Congo, Democratic Republic of Congo, People's Republic of Cook Islands Costa Rica, Republic of Cote D'Ivoire, Ivory Coast, Republic of the Cyprus, Republic of Czech Republic Denmark, Kingdom of Djibouti, Republic of Dominica, Commonwealth of Ecuador, Republic of Egypt, Arab Republic of El Salvador, Republic of Equatorial Guinea, Republic of Eritrea Estonia Ethiopia Faeroe Islands Falkland Islands (Malvinas) Fiji, Republic of the Fiji Islands Finland, Republic of France, French Republic French Guiana French Polynesia French Southern Territories Gabon, Gabonese Republic Gambia, Republic of the Georgia Germany Ghana, Republic of Gibraltar Greece, Hellenic Republic Greenland Grenada Guadaloupe Guam Guatemala, Republic of Guinea, Revolutionary People's Rep'c of Guinea-Bissau, Republic of Guyana, Republic of Heard and McDonald Islands Holy See (Vatican City State) Honduras, Republic of Hong Kong, Special Administrative Region of China Hrvatska (Croatia) Hungary, Hungarian People's Republic Iceland, Republic of India, Republic of Indonesia, Republic of Iran, Islamic Republic of Iraq, Republic of Ireland Israel, State of Italy, Italian Republic Japan Jordan, Hashemite Kingdom of Kazakhstan, Republic of Kenya, Republic of Kiribati, Republic of Korea, Democratic People's Republic of Korea, Republic of Kuwait, State of Kyrgyz Republic Lao People's Democratic Republic Latvia Lebanon, Lebanese Republic Lesotho, Kingdom of Liberia, Republic of Libyan Arab Jamahiriya Liechtenstein, Principality of Lithuania Luxembourg, Grand Duchy of Macao, Special Administrative Region of China Macedonia, the former Yugoslav Republic of Madagascar, Republic of Malawi, Republic of Malaysia Maldives, Republic of Mali, Republic of Malta, Republic of Marshall Islands Martinique Mauritania, Islamic Republic of Mauritius Mayotte Micronesia, Federated States of Moldova, Republic of Monaco, Principality of Mongolia, Mongolian People's Republic Montserrat Morocco, Kingdom of Mozambique, People's Republic of Myanmar Namibia Nauru, Republic of Nepal, Kingdom of Netherlands Antilles Netherlands, Kingdom of the New Caledonia New Zealand Nicaragua, Republic of Niger, Republic of the Nigeria, Federal Republic of Niue, Republic of Norfolk Island Northern Mariana Islands Norway, Kingdom of Oman, Sultanate of Pakistan, Islamic Republic of Palau Palestinian Territory, Occupied Panama, Republic of Papua New Guinea Paraguay, Republic of Peru, Republic of Philippines, Republic of the Pitcairn Island Poland, Polish People's Republic Portugal, Portuguese Republic Puerto Rico Qatar, State of Reunion Romania, Socialist Republic of Russian Federation Rwanda, Rwandese Republic Samoa, Independent State of San Marino, Republic of Sao Tome and Principe, Democratic Republic of Saudi Arabia, Kingdom of Senegal, Republic of Serbia and Montenegro Seychelles, Republic of Sierra Leone, Republic of Singapore, Republic of Slovakia (Slovak Republic) Slovenia Solomon Islands Somalia, Somali Republic South Africa, Republic of South Georgia and the South Sandwich Islands Spain, Spanish State Sri Lanka, Democratic Socialist Republic of St. Helena St. Kitts and Nevis St. Lucia St. Pierre and Miquelon St. Vincent and the Grenadines Sudan, Democratic Republic of the Suriname, Republic of Svalbard & Jan Mayen Islands Swaziland, Kingdom of Sweden, Kingdom of Switzerland, Swiss Confederation Syrian Arab Republic Taiwan, Province of China Tajikistan Tanzania, United Republic of Thailand, Kingdom of Timor-Leste, Democratic Republic of Togo, Togolese Republic Tokelau (Tokelau Islands) Tonga, Kingdom of Trinidad and Tobago, Republic of Tunisia, Republic of Turkey, Republic of Turkmenistan Turks and Caicos Islands Tuvalu Uganda, Republic of Ukraine United Arab Emirates United Kingdom of Great Britain & N. Ireland Uruguay, Eastern Republic of Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Viet Nam, Socialist Republic of Wallis and Futuna Islands Western Sahara Yemen Zambia, Republic of Zimbabwe

Original post:

MCC students inducted into new honor society geared toward biology - Mohave Valley News

FRIDAY FACULTY FEATURE: Boente’s Biology Background the Rock Online – The Rock Online

Bee-o-int-te, Bo-int, Boe-net. All three different ways to say her name, but all are incorrect.

Boente, pronounced Bent-te, is one of the eighteen science teachers within the school department.

Boente went to the University of Iowa for two years before transferring to the University of Illinois for the last two years of her undergraduate degree. Boente began teaching after graduating from Illinois, starting as a substitute teacher at Lincoln Park High School, where she eventually became a teacher for two years.

She then moved to Colorado and began teaching in the Aurora Public Schools District at Vista Peak High School. After the principal of her last school left, she began looking for a different career path. Boente applied for a position at Rock Canyon.

[Rock Canyon is] definitely the best school Ive taught at, Im definitely the happiest here, Boente said. I do miss parts of the other schools. I miss the diversity, the different points of views and things like that, people from different backgrounds.

Growing up, Boente never really had a dream career but can always remember looking at teaching and thinking of a career in it.

I think that I just always wanted to be one, Boente said. I remember in first grade, when we dressed up as what we wanted to be when were older. I [dressed] up as a teacher and I think its just what I like to picture myself as.

Boente is currently in year five as a Jag and year 10 of teaching total.

My degree is I majored in Integrative Biology, and I minored in chemistry at U of I, and then I went to DePaul in Chicago and I got my masters in secondary science education, Boente said.

Even though teaching has always been something Boente has had an interest in and loved doing, if she could have a dream job, she would be a genetic counselor.

I teach genetics. Its obviously something that I find really interesting, Boente said. That field allows you to really kind of combine the science piece and also the working with people piece. So I do get that in teaching but its just kind of a completely different application to things. I just find it super interesting.

The application of science combined with helping people is what makes the job so interesting to her.

I think that [genetic counseling is] something thats always going to have a need for jobs, Boente said. Theres a lot of need for that position because we have lots of different technologies. A lot of the time, its used when people are trying to have children, and now that we have lots of technology as far as in vitro fertilization and that kind of stuff, theres just definitely going to be a need for it and just the whole field of genetics.

Boente teaches regular Biology, a class mostly taken by sophomores, and also teaches Genetics, an elective that any student can take.

While Boente currently only teaches science, she grew up playing volleyball and coached volleyball for a few seasons.

I played [for] like my whole life before that and I used to coach [at Rock Canyon] so its definitely one of my favorite things, Boente said. I volunteered my first year, so that was 2019 [to] 2020 but I wasnt really like a coach that year. So I would say from 2020 to 2022 [I coached]. So I think I did it for three seasons.

She was the sophomore girls volleyball coach for two years and then was the head JV boys volleyball coach for the 2020 season. The team only had one game due to COVID-19 interrupting the season.

We won [that game], Boente said. And then we didnt have a season after that. So we technically went undefeated.

While Boente does not coach anymore, she spends her free time with her daughter Mackie and also enjoys kickboxing.

I have a heavy bag in my basement, but I just dont use it very often, Boente said.

Before having her daughter, Boente would find herself up in the mountains skiing almost every weekend with her husband when they moved from Illinois to Colorado.

Skiing is something [that I enjoy], thats like one of the main reasons that we moved out here is because we both love to ski and we both love the mountains, Boente said.

Boente spends her time in room 9200 throughout the day, helping students and teaching.

[Rock Canyon] is definitely the best school Ive taught at, Boente said. Thats why Ive stayed here.

More:

FRIDAY FACULTY FEATURE: Boente's Biology Background the Rock Online - The Rock Online

Measuring the Intelligence of a Cell – University of California San Diego

What is Quantitative Biology and Why Does it Matter? As explained by Pradipta Ghosh

Our group is fascinated with molecules inside the cell popularly referred to as switches, because they control the flow of information inside a cell and between the cell and its external environment. A long-held belief was that one class of switch solely senses the outside environment, such as lower oxygen availability, while another class of switch solely coordinates communication within the cell, such as telling the genes to produce different proteins. Finding out whether the two types of switches interact has been elusive.

This is because cells are tiny, and the switches even tinier! There are many compelling mysteries that we biologists are still chipping away at, aided by technological advances with each passing decade.

Through these advances, we have recently discovered a circuit that combines both types of switches and allows the cell to sense its environment and mount a fitting response to it. To investigate how this circuit works in commanding a cells behavior, we now need to approach it as engineers, i.e., by building it as an electrical circuit in a virtual cell model.

To do so, we must use quantitative biology to gather measurements from the real world and feed those measurements to inform the model. Such a model, if built right, can have predictive power to ask questions that have never been possible before, and further our insights into how cells behave as intelligent machines that adapt to changing environments.

The scientists who build the modelsmathematicians, computational biologists, systems engineersneed numbers. At what second does the switch turn on? For how long? To answer their questions, we need assays that get precise measurements of whats happening in the cells interior. Thats the type of technology well have at the Agilent Center of Excellence for Cellular Intelligence.

Once the model is built, it becomes a virtual cell that we can tinker with, visualizing its behavior if we lower the oxygen supply or put it into chemotherapy. In this way, predictive models allow us to create an intervention and ask how it changes the cells behavior. If, for instance, I add a drug that will take out one of the switches, can I prevent a tumor cell from metastasizing?

This is how quantitative biology, advanced technology, and multidisciplinary research synergize to save peoples lives.

Link:

Measuring the Intelligence of a Cell - University of California San Diego

Shy sea anemones are more likely to survive heatwaves – EurekAlert

image:

Sea anemones that live on the rocky coasts of the Atlantic are exposed to large differences in water temperature. Depending on the individual's personality, they cope with the heat differently.

Credit: Jack Thomson

Even in nature, pride can prevail. A study with researchers from the University of Gothenburg shows that sea anemones that react more slowly to change can survive a heatwave better than individuals that change their behaviour quickly.

Along the Atlantic coasts of Europe, many species are exposed to abrupt shifts in habitat. Tides, storms and rapid temperature changes are commonplace for the marine species that live there. With climate change, heatwaves are expected to become more frequent, and researchers wanted to find out how coastal marine species cope with extreme water temperatures. They chose to study the sea anemone species Actinia equina, a species that exhibits individual behaviours.

Brave or shy

We call them animal personalities. They are different behavioural life strategies found in the same species. The anemones we studied have two personality traits, bold and shy, and in extreme heat waves the shy anemones do better, says Lynne Sneddon, a zoophysiologist at the University of Gothenburg and co-author of the study published in the Journal of Experimental Biology.

Being a shy or bold anemone describes the individual's risk-taking. Both behaviours have advantages that have made them winners in evolution, otherwise they would not exist. A bold anemone reacts more quickly to changes in the environment than a shy anemone does. This means that the bold ones are quicker than the shy ones to open their tentacles to forage after a change. The bold anemones can trap more of the nutrients in the water, and this gives them a competitive advantage. On the other hand, they become more vulnerable in extreme conditions, such as heat waves. The researchers' study shows that being a shy individual is a better survival strategy when the water is extremely hot.

We measured the metabolism of the anemones and could see that when the water temperature was high, the metabolism of the bold anemones skyrocketed. This meant that they had to increase their nutrient intake so much that they risked dying. The shy anemones' metabolism increased less, so they were better able to cope with the heat stress, says Lynne Sneddon.

Rapid warming at low tide

In coasts with large tidal differences, water collects in rock pools that warm up quickly on the ebb tide before the next flood washes in with colder seawater. Anemones living in these pools are therefore particularly vulnerable to large temperature differences.

Heat waves will become more common in the future and cold-blooded animals may find it difficult to cope. We studied anemones, but we have reason to believe that the phenomenon applies to other species as well. If the animals can't cope, there will be a disruption in the ecosystems and this could have implications for the whole food web, says Lynne Sneddon.

Journal of Experimental Biology

Experimental study

Animals

Differential metabolic responses in bold and shy sea anemones during a simulated heatwave

7-Feb-2024

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Go here to read the rest:

Shy sea anemones are more likely to survive heatwaves - EurekAlert

Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies … – GlobeNewswire

MARLBOROUGH, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company, today announced it will highlight case studies featuring its Spatial Biology 2.0 Solutions that enable unprecedented speed and scale for spatial biology studies at the American Association for Cancer Research (AACR) 2024 Annual Meeting in San Diego, April 5 to 10. In addition, the company will showcase new applications of its PhenoCode Signature Panels and preliminary data from the Thermo Fisher ViewRNA assays on Akoyas platforms.

Presentations Showcase the Power of Spatial Biology 2.0

Industry-leading capabilities of the companys spatial biology platforms will be presented during Akoyas Spotlight Theater, titled Spatial Biology 2.0: Spatial Insights and Precision Medicine at Unprecedented Scale on Monday, April 8 at 3 PM (PST). The event will describe how researchers are revealing new insights into the tumor microenvironment, elucidating the mechanisms of cancer treatment response, and paving the way for spatial biology to impact patient outcomes. Deployment of Akoyas PhenoCycler-Fusion 2.0, PhenoImager HT 2.0, and PhenoCode Panels across the research continuum, from ultrahigh-plex discoveries to actionable signatures, will be described by the presenters:

Dr. Kulasinghe will also present a talk entitled Ultra high-plex profiling of the tumor microenvironment on April 6 from 12:36 PM - 12:54 PM PT in Session MW14 - Choosing and Using Antibodies for Spatial Informed Protein Expression. He will discuss the development of ultrahigh-plex antibody panels for the comprehensive characterization of the tumor microenvironment.

Spatial Biology 2.0 Solutions Displayed at Booth #247

Akoya Biosciences will demonstrate new uses of its PhenoCode Signature Panels for accelerating discovery and validation of spatial biomarkers using the PhenoImager HT 2.0 platform. The company will also present initial findings from the Thermo Fisher Scientific ViewRNA assays on the PhenoCycler-Fusion 2.0.

Poster Presentations

Several studies featuring Akoyas Spatial Biology platforms will be described in the following posters:

Monday, April 8: 9:00 AM 12:30 PM

Poster 1525: Integration of high-plex tumor-Immune phenotyping and checkpoint interactions for deeper spatial characterization of human cancer tissues. S. Bodbin, Navinci Diagnostics et al.

Monday, April 8: 1:30 PM 5:00 PM

Poster 3623: Quantifying pharmacodynamic markers of radioligand therapies in tumor by multiplex immunofluorescence and automated quantitative analysis (AQUA) algorithms. J. Santos, Navigate BioPharma Services, Inc. et al.

Poster 3651: Mutational analysis and spatial phenotyping to decipher racial disparities in pancreatic adenocarcinoma; D. J. Salas-Escabillas, University of Michigan et al.

Poster 3763: Comparative spatial analyses of the tumor immune landscape in different mouse models of glioblastoma; D. Klymyshyn, Akoya Biosciences et al.

Tuesday, April 9: 9:00 AM 12:30 PM

Poster 3988: Deep spatial immunophenotyping of lymphoid aggregates in pancreatic cancer using multi-omic integration of ultra high-plex proteomics and transcriptomics; D. Gong, Massachusetts Institute of Technology (MIT) et al.

Poster 5503: Ultrahigh-plex spatial phenotyping of head and neck cancer tissue uncovers multiomic signatures of immunotherapy response; A. Pratapa, Akoya Biosciences et al.

Poster 5504: Integrating ultrahigh-plex spatial phenotyping: From discovery to clinical applications, A. Pratapa; Akoya Biosciences et al.

Tuesday, April 9: 1:30 PM 5:00 PM

Poster 5507: High-resolution spatial atlas reveals insight into spatial landscape of lung cancer and chronic lung diseases; R. Nandigama, Justus Liebig University et al.

Poster 5508: Single-cell spatial landscape of the mutation-specific human lung tumor immune microenvironment; R. Nandigama, Justus Liebig University et al.

Wednesday, April 10: 9:00 AM 12:30 PM

Poster 6738: Overlapping and distinct mechanisms of effective neoantigen cancer vaccines and immune checkpoint therapy; S. Keshari, UT MD Anderson Cancer Center et al.

Poster 6872: A spatio-temporal approach to mapping the dynamics of cutaneous squamous cell carcinoma progression and immunotherapy response: A journey through TiME; N. Jhaveri, Akoya Biosciences et al.

Network of CROs Providing Spatial Biology Services Continues to Grow

Thirteen of Akoyas twenty qualifiedCRO service providerswill also be exhibiting at AACR. Akoyas CRO network continues to grow rapidly, reflecting the demand for spatial phenotyping solutions across the biopharmaceutical industry. Offering biomarker testing services, these CROs enable drug developers and academic research institutions to accelerate the discovery and development of new immuno-therapies.

Full details about Akoyas AACR activities and poster presentations can be found here.

Forward Looking Statements

This press release contains forward-looking statements that are based on managements beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our expectations about the potential and utility of our products and services, the market demand for spatial phenotyping solutions and predictions regarding the future impact of spatial biology.

In some cases, you can identify forward-looking statements by the words may, will, could, would, should, expect, intend, plan, anticipate, believe, estimate, predict, project, potential, continue, ongoing or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

About Akoya Biosciences

As The Spatial Biology Company, Akoya Biosciences mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The Company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode Panels and PhenoCycler, PhenoImager Fusion and PhenoImager HT Instruments. To learn more about Akoya, visitwww.akoyabio.com.

Investor Contact:

Priyam Shah Sr. Director, Investor Relations Akoya Biosciences investors@akoyabio.com

Media Contact:

Christine Quern 617-650-8497 media@akoyabio.com

Visit link:

Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies ... - GlobeNewswire

BD Increases Access to Cutting-Edge Image-Enabled, Spectral Cell Sorters – BioSpace

New BD FACSDiscover S8 Cell Sorters to Enable More Researchers to Push the Boundaries of Discovery

FRANKLIN LAKES, N.J., April 5, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the global commercial release of new cell sorters that will enable more researchers in a broader range of fields, including cell biology, cancer research and immunology, to reveal insights that were previously invisible in traditional flow cytometry experiments.

The new BD FACSDiscover S8 Cell Sorters feature BD CellView Image Technology, profiled on the cover of the journal Science in 2022, and BD SpectralFX Technology bringing to market breakthrough innovations in real-time imaging and spectral flow cytometry. The three- and four-laser additions to the BD FACSDiscover S8 Cell Sorter family complement the five-laser instrument launched last year and provide scientists greater access, options, and flexibility to incorporate real-time imaging and spectral cell sorting technology in their labs.

"For my research in cellular biology, the instrument was perfectly configured when it came to number of lasers and imaging capabilities," said Daniel Schraivogel, Ph.D., a research staff scientist at EMBL, who estimates he had 600 hours working on the three-laser prototype. "It has the same sorting speed and software capabilities as the five-laser unit, making experiments extremely scalable on an easy-to-use instrument."

Using the FACSDiscover S8 Cell Sorters, researchers can confirm complex biological and spatial insights in real time, obtain individual cell images and isolate desired cells based on visual characteristics at high speeds, all within a simplified and easy to use workflow. BD CellView Image Technology improves sort and sample quality, bringing confidence to biological results and saving researchers time and cost in their downstream applications. This expedited time to insight expands capabilities for researchers to transform research and cell-based therapeutic development across numerous fields in drug discovery, immuno-oncology and genomics.

"In flow cytometry, there are often 'suspect' populations where cells are dead or dying, and doublets and cellular debris that can impact the integrity of experiments," Schraivogel continued. "In addition to the added value of spatial information that is needed for many projects in cell biology, infection biology and functional genomic screening, the imaging sorter allows us to better explore our cell populations and is used to validate true single-cell gating and sorting, to deliver better-quality cells and biological outputs."

The family of BD FACSDiscover Cell Sorters will be featured at upcoming conferences beginning with the American Association for Cancer Research (AACR) Annual Meeting, April 5-10, and is now available to order through local sales representatives. More information is available at bdbiosciences.com/S8.

About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at http://www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson.

View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-increases-access-to-cutting-edge-image-enabled-spectral-cell-sorters-302108936.html

SOURCE BD (Becton, Dickinson and Company)

Company Codes: NYSE:BDX

Original post:

BD Increases Access to Cutting-Edge Image-Enabled, Spectral Cell Sorters - BioSpace

We’ve had bird evolution all wrong – EurekAlert

image:

A greater flamingo in Mallorca, Spain. Unraveling a genetic mystery revealed that flamingos and doves are more distantly related than previously thought.

Credit: Daniel J. Field

An enormous meteor spelled doom for most dinosaurs 65 million years ago. But not all. In the aftermath of the extinction event, birds technically dinosaurs themselves flourished.

Scientists have spent centuries trying to organize and sort some 10,000 species of birds into one clear family tree to understand how the last surviving dinosaurs filled the skies. Cheap DNA sequencing should have made this simple, as it has for countless other species.

But birds were prepared to deceive us.

In a pair of new research papers released today, April 1, scientists reveal that another event 65 million years ago misled them about the true family history of birds. They discovered that a section of one chromosome spent millions of years frozen in time, and it refused to mix together with nearby DNA as it should have.

This section, just two percent of the bird genome, convinced scientists that most birds could be grouped into two major categories, with flamingos and doves as evolutionary cousins. The more accurate family tree, which accounts for the misleading section of the genome, identifies four main groups and identifies flamingos and doves as more distantly related.

My lab has been chipping away at this problem of bird evolution for longer than I want to think about, said Edward Braun, Ph.D., the senior author of the paper published in the Proceedings of the National Academy of Sciences and a professor of biology at the University of Florida. We had no idea there would be a big chunk of the genome that behaved unusually. We kind of stumbled onto it.

Braun supervised an international team of collaborators led by Siavash Mirarab, a professor of computer engineering at the University of California San Diego, to publish their evidence that this sticky chunk of DNA muddied the true history of bird evolution. Mirarab and Braun also contributed to a companion paper published in Nature that outlines the updated bird family tree, which was led by Josefin Stiller at the University of Copenhagen.

Both papers are part of the B10K avian genomics project led by Guojie Zhang of Zhejiang University, Erich Jarvis of Rockefeller University, and Tom Gilbert of the University of Copenhagen.

Ten years ago, Braun and his collaborators pieced together a family tree for the Neoaves, a group that includes the vast majority of bird species. Based on the genomes of 48 species, they split the Neoaves into two big categories: doves and flamingos in one group, all the rest in the other. When repeating a similar analysis this year using 363 species, a different family tree emerged that split up doves and flamingos into two distinct groups.

With two mutually exclusive family trees in hand, the scientists went hunting for explanations that could tell them which tree was correct.

When we looked at the individual genes and what tree they supported, all of a sudden it popped out that all the genes that support the older tree, theyre all in one spot. Thats what started the whole thing, Braun said.

Investigating this spot, Brauns team noticed it was not as mixed together as it should have been over millions of years of sexual reproduction. Like humans, birds combine genes from a father and a mother into the next generation. But birds and humans alike first mix the genes they inherited from their parents when creating sperm and eggs. This process is called recombination, and it maximizes a species genetic diversity by making sure no two siblings are quite the same.

Brauns team found evidence that one section of one bird chromosome had suppressed this recombination process for a few million years around the time the dinosaurs disappeared. Whether the extinction event and the genomic anomalies are related is unclear.

The result was that the flamingos and doves looked similar to one another in this chunk of frozen DNA. But taking into account the full genome, it became clear that the two groups are more distantly related. Whats surprising is that this period of suppressed recombination could mislead the analysis, Braun said. And because it could mislead the analysis, it was actually detectable more than 60 million years in the future. That's the cool part.

Such a mystery could be lurking in the genomes of other organisms as well.

We discovered this misleading region in birds because we put a lot of energy into sequencing birds genomes, Braun said. I think there are cases like this out there for other species that are just not known right now.

This work was supported in part by the National Science Foundation.

Proceedings of the National Academy of Sciences

Data/statistical analysis

Not applicable

A region of suppressed recombination misleads neoavian phylogenomics

1-Apr-2024

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Here is the original post:

We've had bird evolution all wrong - EurekAlert

Altered brain morphology and functional connectivity in postmenopausal women – EurekAlert

image:

Figure 6.Between-group comparison map (premenopausal women vs. postmenopausal women) of the left mOFC functional connectivity.

Credit: 2024 Kim et al.

[...] our findings suggest that diminished brain volume and functional connectivity may be linked to menopause-related symptoms caused by the lower sex hormone levels.

BUFFALO, NY- April 1, 2024 A new research paper was published on the cover of Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 6, entitled, Altered brain morphology and functional connectivity in postmenopausal women: automatic segmentation of whole-brain and thalamic subnuclei and resting-state fMRI.

The transition to menopause is associated with various physiological changes, including alterations in brain structure and function. However, menopause-related structural and functional changes are poorly understood. In this new study, researchers Gwang-Won Kim, Kwangsung Park, Yun-Hyeon Kim, and Gwang-Woo Jeong from Chonnam National University not only compared the brain volume changes between premenopausal and postmenopausal women, but also evaluated the functional connectivity between the targeted brain regions associated with structural atrophy in postmenopausal women.

To the best of our knowledge, no comparative neuroimaging study on alterations in the brain volume and functional connectivity, especially focusing on the thalamic subnuclei in premenopausal vs. postmenopausal women has been reported.

Each of the 21 premenopausal and postmenopausal women underwent magnetic resonance imaging (MRI). T1-weighted MRI and resting-state functional MRI data were used to compare the brain volume and seed-based functional connectivity, respectively. In statistical analysis, multivariate analysis of variance, with age and whole brain volume as covariates, was used to evaluate surface areas and subcortical volumes between the two groups.

Postmenopausal women showed significantly smaller cortical surface, especially in the left medial orbitofrontal cortex (mOFC), right superior temporal cortex, and right lateral orbitofrontal cortex, compared to premenopausal women (p < 0.05, Bonferroni-corrected) as well as significantly decreased functional connectivity between the left mOFC and the right thalamus was observed (p < 0.005, Monte-Carlo corrected). Although postmenopausal women did not show volume atrophy in the right thalamus, the volume of the right pulvinar anterior, which is one of the distinguished thalamic subnuclei, was significantly decreased (p < 0.05, Bonferroni-corrected).

Postmenopausal women showed significantly lower left mOFC, right lOFC, and right STC surface areas, reduced right PuA volume, and decreased left mOFC-right thalamus functional connectivity compared to premenopausal women. If replicated in an independent sample, these findings will be helpful for understanding the effects of menopause on the altered brain volume and functional connectivity in postmenopausal women.

Read the full study: DOI: https://doi.org/10.18632/aging.205662

Corresponding Author: Gwang-Woo Jeong - gwjeong@jnu.ac.kr

Keywords: brain morphology, functional connectivity, sex hormones, thalamic subnuclei

Click here to sign up for free Altmetric alerts about this article.

About Aging:

Aging publishes research papers in all fields of aging research including but not limited, aging from yeast to mammals, cellular senescence, age-related diseases such as cancer and Alzheimers diseases and their prevention and treatment, anti-aging strategies and drug development and especially the role of signal transduction pathways such as mTOR in aging and potential approaches to modulate these signaling pathways to extend lifespan. The journal aims to promote treatment of age-related diseases by slowing down aging, validation of anti-aging drugs by treating age-related diseases, prevention of cancer by inhibiting aging. Cancer and COVID-19 are age-related diseases.

Aging is indexed by PubMed/Medline (abbreviated as Aging (Albany NY)), PubMed Central, Web of Science: Science Citation Index Expanded (abbreviated as AgingUS and listed in the Cell Biology and Geriatrics & Gerontology categories), Scopus (abbreviated as Aging and listed in the Cell Biology and Aging categories), Biological Abstracts, BIOSIS Previews, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).

Please visit our website at http://www.Aging-US.com and connect with us:

Click here to subscribe to Aging publication updates.

For media inquiries, please contact media@impactjournals.com.

Aging (Aging-US) Journal Office

6666 E. Quaker Str., Suite 1B

Orchard Park, NY 14127

Phone: 1-800-922-0957, option 1

###

Observational study

People

Altered brain morphology and functional connectivity in postmenopausal women: automatic segmentation of whole-brain and thalamic subnuclei and resting-state fMRI

23-Mar-2024

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

See more here:

Altered brain morphology and functional connectivity in postmenopausal women - EurekAlert